Breadcrumb

Breadcrumbs

Press Releases

Press Releases

News, Events, Updates, Breakthroughs

Journalists may direct questions to mediainquiries@dsi.com. Or click here for direct contact information for Daiichi Sankyo U.S. Public Affairs team

Press announcements are archived by release date, searchable by topic:

From To
Date Title
Mon Jan 14 00:00:00 GMT-04:00 2019
Daiichi Sankyo Initiates Pivotal Phase 3 Trial of [Fam-] Trastuzumab Deruxtecan (DS-8201) in HER2 L ...
PDF (265 KB)
Wed Dec 19 00:00:00 GMT-04:00 2018
Daiichi Sankyo Initiates First Novel-Novel Combination Study of Two Investigational Agents within i ...
PDF (140 KB)
Mon Dec 17 00:00:00 GMT-04:00 2018
Daiichi Sankyo Out-Licenses ROS1/NTRK Inhibitor DS-6051 to AnHeart Therapeutics
PDF (244 KB)
Mon Dec 10 00:00:00 GMT-04:00 2018
Daiichi Sankyo and Sarah Cannon Research Institute Launch Strategic Collaboration to Develop Novel ...
PDF (313 KB)
Sat Dec 08 00:00:00 GMT-04:00 2018
Daiichi Sankyo Presents Updated Phase 1 Results of [Fam-] Trastuzumab Deruxtecan (DS-8201) in Patie ...
PDF (275 KB)
Wed Dec 05 00:00:00 GMT-04:00 2018
Daiichi Sankyo Presents Updated Phase 1 Data for U3-1402 in Patients with HER3-Expressing Metastati ...
PDF (439 KB)
Mon Dec 03 00:00:00 GMT-04:00 2018
Comprehensive Analyses from Pivotal Phase 3 QuANTUM-R Study Demonstrate Consistent Overall Survival ...
PDF (249 KB)
Tue Nov 27 00:00:00 GMT-04:00 2018
Daiichi Sankyo and Roche to Collaborate on New HER2 Low Companion Diagnostic Test
PDF (239 KB)
Wed Nov 21 00:00:00 GMT-04:00 2018
FDA Grants Priority Review for Daiichi Sankyo’s New Drug Application for FLT3 Inhibitor Quizartinib ...
PDF (246 KB)
Mon Nov 05 00:00:00 GMT-04:00 2018
EMA Validates and Grants Accelerated Assessment of Marketing Authorization Application for Daiichi ...
PDF (245 KB)
Showing 1 - 10 of 41 results.

Press Release More Stories

More Stories

Who We Are

As the U.S. subsidiary of a global pharmaceutical innovator, Daiichi Sankyo, Inc. draws on a rich heritage of innovation, integrity and accountability..

read more ...